3:54 PM
Apr 10, 2018
 |  BC Innovations  |  Distillery Therapeutics



In vitro and mouse studies identified an α-galactosylceramide (α-GalCer)-based antigen that could enhance the antitumor immunity of invariant natural killer T (NKT) cells to treat metastatic melanoma. Chemical synthesis and in vitro binding assays of α-GalCer...

Read the full 167 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >